WELL Health Launches Its AI-powered Co-pilot for Cardiologists Powered by HEALWELL AI to Help Improve Detection of Cardiovascular Disease
WELL Health Launches Its AI-powered Co-pilot for Cardiologists Powered by HEALWELL AI to Help Improve Detection of Cardiovascular Disease
- WELL has launched its new AI-powered physician co-pilot to assist cardiologists in better identifying patients at high risk of cardiovascular disease ("CVD"). WELL is exclusively partnering with HEALWELL AI, a leader in AI enabled disease diagnosis, as an extension of the WELL AI Decision Support ("WAIDS") product offering.
- The co-pilot will be deployed into WELL Diagnostic Centres, Canada's largest cardiology and medical diagnostic group, providing support and assisting cardiologists in over 40 locations across Ontario.
- CVD stands as the leading cause of death globally, accounting for approximately 32% of deaths worldwide in 2019(1), underscoring the critical need for early detection. HEALWELL also expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization ("CRO"), BioPharma Services Inc.
- WELL推出了全新的人工智能輔助醫師,幫助心臟病專家更好地識別高風險心血管疾病(“CVD”)。WELL獨家與AI療愈AI合作,作爲WELL AI決策支持(“WAIDS”)產品的擴展提供服務。
- 該輔助功能將部署到WELL診斷中心,加拿大最大的心臟病和醫學診斷集團,在安大略省的40多個地點提供支持並協助心臟病專家。
- CVD是全球最主要的死因,約佔2019年全球死亡人數的32%(1),凸顯了早期檢測的重要性。 HEALWELL還期望利用這項技術,幫助加速與CVD相關的生命科學研究和開發機會,併爲其新收購的臨床研究組織(“CRO”)BioPharma Services Inc推動新的業務機會。
Vancouver, British Columbia and Toronto, Ontario--(Newsfile Corp. - July 17, 2024) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or the "Company") a digital health company focused on tech-enabling healthcare providers, and its investee company, HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL"), a healthcare technology company focused on AI and data science for preventative care, are jointly pleased to announce the launch of WELL's AI-powered co-pilot for cardiologists exclusively powered by HEALWELL AI, aimed at identifying patients at high risk of cardiovascular disease ("CVD"). This significant expansion of WELL's AI capabilities builds on the success of its second-generation AI-powered physician co-pilot, WELL AI Decision Support ("WAIDS"), developed exclusively in partnership with HEALWELL. This enhancement adds to its existing rare and chronic disease detection abilities and is an extension to the WAIDS offering.
加拿大溫哥華和安大略多倫多 -(Newsfile Corp. - 2024年7月17日) - WELL Health Technologies Corp.(TSX:WELL)(OTCQX:WHTCF)(“WELL”或“公司”)是一家數字健康公司,專注於技術使醫療保健提供者具備科技支持,以及其投資公司HEALWELL AI Inc.(TSX:AIDX)(OTCQX:HWAIF)(“HEALWELL”),一家專注於AI和數據科學的醫療技術公司,專注於預防保健。它們共同高興地宣佈WELL人工智能心臟病輔助功能的推出,由HEALWELL AI獨家提供支持,旨在識別高風險心血管疾病(“CVD”)的患者。WELL的這項重大擴張旨在建立在第二代人工智能醫師副駕駛員WELL AI決策支持(“WAIDS”)成功之上。WAIDS與HEALWELL獨家合作開發。此增強功能增加了其現有的罕見和慢性疾病檢測能力,並是WAIDS提供的擴展。
The co-pilot for cardiologists will be deployed in WELL Diagnostics Centres, Canada's largest cardiology and medical diagnostic group with over 40 locations in Ontario. It will be available to cardiologists within the WELL Diagnostic Centres ecosystem, providing invaluable support in the early detection and management of cardiovascular disease.
心臟病專家的輔助功能將部署在加拿大最大的心臟病和醫學診斷集團WELL診斷中心,在安大略省的40多個地點提供支持,在早期檢測和管理心血管疾病方面提供寶貴的支持。
Dina Sergi, CEO of WELL Diagnostic Centres, highlighted the tool's impact, "The integration of HEALWELL's AI-powered co-pilot for cardiologists into our WELL Diagnostic Centres represents a game-changing advancement. By offering precise risk stratification and actionable insights, this tool enhances their ability to proactively manage cardiovascular health and improve patient care."
WELL Diagnostic Centres的首席執行官Dina Sergi強調了這種工具的影響:“將HEALWELL的AI輔助心臟病機組融入我們的WELL Diagnostic Centres中,代表了改變卡牌遊戲的進展。通過提供精準的風險分層和可操作的見解,該工具提高了他們預防性管理心血管健康並改善患者護理的能力。”
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, "The launch of our AI-powered co-pilot for specialists marks a significant milestone in our mission to enhance healthcare through advanced technology. By expanding our AI capabilities to include cardiovascular disease detection, we are equipping cardiologists with enhanced tools and decision support necessary to identify at-risk patients earlier, ultimately improving patient outcomes and reducing healthcare costs. The integration of this tool into WELL's Diagnostic Centres is particularly important, as it provides us access to Canada's largest cardiology group. This vast dataset not only assists hundreds of cardiologists within the WELL Diagnostic Centres ecosystem but also allows us to continuously refine and enhance the co-pilot."
HEALWELL的首席執行官Alexander Dobranowski博士評論道:“爲專家推出人工智能副駕駛員標誌着我們通過先進技術增強醫療保健的重要里程碑。通過將我們的AI能力擴展到包括心血管疾病檢測,我們爲心臟病專家提供了必要的增強工具和決策支持,能夠更早地識別有風險的患者,最終提高患者結果並降低醫療保健成本。將這個工具集成到WELL的診斷中心特別重要,因爲它爲我們提供了加拿大最大的心臟病集團的接入機會。這個龐大的數據集不僅爲WELL診斷中心生態系統中的數百名心臟病專家提供幫助,而且還允許我們不斷完善和改進輔助駕駛員。”
Dr. Paul Kannampuzha, Chief Cardiology Officer of WELL Diagnostic Centres commented. "As a cardiologist, I am encouraged by how AI can help provide improved disease detection and decision support for cardiologists across the country. I believe this technology will help drive improved preventative care and ensure patients don't fall through the cracks."
WELL Diagnostic Centres的主任心臟病醫學官Paul Kannampuzha博士發表評論:“作爲心臟病專家,我對人工智能如何幫助提供改進的疾病檢測和決策支持感到鼓舞。我相信這項技術將有助於推動改進預防性保健,並確保患者不被遺漏。”
Cardiovascular disease (CVD) is a group of disorders affecting the heart and blood vessels and is the leading cause of death globally, responsible for approximately 32% of deaths worldwide in 2019(1). In Canada, recent estimates suggest that CVD costs about $22 billion per year and is considered the second leading contributor to healthcare costs(2). Identifying patients with worsening cardiovascular conditions earlier is crucial, as cardiovascular disease is the third leading cause of death in Canada.
心血管疾病(CVD)是影響心臟和血管的一組疾病,是全球首要死因,佔2019年全球死亡人數的約32%,在加拿大,最近的估計表明,CVD每年花費約220億美元,是健康保健成本的第二大貢獻者(2)。早期識別惡化的心血管疾病患者至關重要,因爲心血管疾病是加拿大第三大死因。
The global market for pharmaceutical drugs supporting cardiovascular disease was valued at approximately USD 144.1 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% over the next decade, reaching an estimated USD 207.8 billion by 2033 (Precedence Research)(3). HEALWELL expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization (CRO), BioPharma Services Inc.
製藥支持心血管疾病的全球市場價值約爲1,441億美元,預計在未來十年內將以約4%的複合年增長率增長,達到預計的2033億美元(Precedence Research)(3)。HEALWELL預計將利用這項技術,幫助加速與CVD相關的生命科學研究和開發機會,併爲其新收購的臨床研究組織(CRO)BioPharma Services Inc推動新的業務機會。
Footnotes:
腳註:
About WELL Health Technologies Corp.
關於WELL健康科技公司
WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 34,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 175 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF". To learn more about WELL, please visit: .
WELL的使命是以技術推動健康服務行業的發展。我們開發了最好的技術、服務和支持,使得健康服務提供商有能力對患者結果產生積極的影響。WELL的全面醫療保健和數字平台包括廣泛的前端和後端管理軟件應用程序,幫助醫生管理和保障他們的工作室。WELL的解決方案讓逾34,000多名醫療服務提供商在美國和加拿大運行,併爲加拿大擁有和經營的最大醫療生態系統提供動力,其中有超過175家診所提供初級護理、專科護理和診斷服務。在美國,WELL的解決方案專注於特定市場,如胃腸市場、婦科、初級護理和心理健康。WELL在多倫多證券交易所以"WELL"爲股票代碼,在場外交易所以"WHTCF"爲股票代碼。想要更多了解WELL,請訪問:。
About HEALWELL AI
HEALWELL是一家專注於AI和數據科學的醫療技術公司,專注於預防保健。其使命是通過疾病的早期識別和發現來改善醫療保健並拯救生命。利用其獨有的專有技術,該公司正在開發和商業化先進的臨床決策支持系統,可以幫助醫療保健提供者檢測罕見和慢性疾病,提高他們的實踐效率,最終幫助提高患者的健康結果。HEALWELL正在執行以技術和臨床科學能力的發展和收購爲中心的戰略,這些能力與公司的路線圖相互補充。HEALWELL在多倫多證券交易所 (TSX) 上公開交易,股票代碼爲“AIDX”,在OTC Exchange上下市,股票代碼爲“HWAIF”。如果想了解更多HEALWELL的信息,請訪問
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit .
HEALWELL是一家專注於預防保健的醫療技術公司,專注於AI和數據科學。其使命是通過早期疾病識別和檢測改善醫療保健,並挽救生命。該公司正在開發和商業化先進的臨床決策支持系統,這些系統可以幫助醫療保健提供者檢測罕見和慢性疾病,提高其實踐的效率,最終幫助改善患者的健康結果。HEALWELL在多倫多證券交易所上市(股票代碼“AIDX”),在OTC Exchange上也上市(股票代碼“HWAIF”)。要了解有關HEALWELL的更多信息,請訪問其網站。
Forward-Looking Statements
前瞻性聲明
Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among other things, the deployment of WAIDS at WELL Health Diagnostic Centres, the use of the WAIDS to improve patient care, and the use of AI technology by HEALWELL to drive research and development opportunities related to CVD. Forward-looking statements are often, but not always, identified by words or phrases such as "opportunity", "potential", "improve", "expect", "intend", "create" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to: the ability of HEALWELL to utilize AI technologies to detect CVD indicators; the ability to collaborate with the pharmaceutical industry for research and development opportunities, HEALWELL's continued compliance with third party intellectual property rights; HEALWELL's continued compliance with privacy laws; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
本新聞稿中的某些聲明構成“前瞻性信息” 和“前瞻性陳述”(統稱爲“前瞻性陳述”)並基於本新聞稿之日的假設、預期、估計和投射。本新聞稿中的前瞻性陳述包括(但並不限於)部署WAIDS在WELL Health Diagnostic Centres的使用、使用WAIDS改進患者護理以及HEALWELL利用AI技術推動與CVD相關的研究和開發機會。前瞻性陳述經常被識別爲使用“機會”、“潛力”、“改進”、“期望”、“打算”、“創造”或這些詞語和短語的變體或表明某些未來條件、行動、事件或結果的陳述,這些未來條件、行動、事件或結果可能“將”、 “可能”、“可能”、“應該”、“可能”或“可以”被採取、發生或實現,或這些術語的否定形式。前瞻性陳述必然基於管理層對歷史趨勢、當前狀況和預期未來發展的認識,以及一些特定因素和假設,儘管在本聲明的日期HEALWELL認爲這些特定因素和假設是合理的,但這些因素和假設是超出HEALWELL控制範圍的,其本質上受到業務、經濟和競爭方面的重大不確定性和意外情況的影響,這些因素和假設可能會導致最終的前瞻性陳述完全或部分不正確或不真實。本新聞稿中的前瞻性陳述是基於各種假設的基礎上,包括但不限於:HEALWELL利用AI技術檢測CVD指標的能力;與製藥行業合作進行研究和開發機會;HEALWELL繼續遵守第三方知識產權的權利;HEALWELL繼續遵守隱私法律;以及下面提到的風險因素,綜合這些風險因素,不會對HEALWELL的業務、運營、收入和/或業績產生重大影響。
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at . The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
HEALWELL的實際結果可能會因許多已知和未知的風險因素而與所述前瞻性陳述表達或暗示的結果、表現、成就或發展有所不同,這些風險因素大多超出HEALWELL的控制範圍。這些風險因素包括但不限於HEALWELL的最新年度信息表格(2024年4月1日)中在“風險因素”一節中討論的因素,在HEALWELL的SEDAR +資料文件檔案中可獲得。這些風險因素不打算代表可能影響HEALWELL的全部因素列表,讀者應謹慎考慮這些和其他因素、不確定性和潛在事件,並不要過度依賴前瞻性陳述。不能保證前瞻性陳述會證明正確,因爲實際結果和未來事件可能會與這些陳述所預測的有所不同。前瞻性陳述是爲提供關於管理層的預期和計劃有關未來的信息而提供的。HEALWELL聲明不打算或不承諾更新或修訂任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因,或解釋隨後實際事件與此類前瞻性陳述之間的任何重大差異,除法律規定之外。本新聞稿中包含的所有前瞻性陳述都受這些警示性聲明的限制。
For more information:
欲了解更多信息:
Tyler Baba
Investor Relations, Manager
WELL Health Technologies Corp.
investor@well.company
604-628-7266
Tyler Baba
投資者關係,經理
corp的WELL技術健康公司。
investor@well.company
604-628-7266
Pardeep S. Sangha
Head of Investor Relations,
HEALWELL AI Inc.
ir@healwell.ai
604-572-6392
Pardeep S. Sangha
投資者關係主管,
關於HEALWELL AI
ir@healwell.ai
604-572-6392